Ireland - English - HPRA (Health Products Regulatory Authority)

pierre fabre medicament - carbocisteine - oral solution - 250/5 mg/ml - carbocisteine

Ireland - English - HPRA (Health Products Regulatory Authority)

pierre fabre medicament - carbocisteine - oral solution - 250/5 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

pierre fabre medicament - carbocisteine - oral solution - 250/5 mg/ml

European Union - English - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. (miol) - ranolazine - angina pectoris - cardiac therapy - ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).,

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

beige pharmaceuticals cc - suspension - each 5 ml suspension contains bismuth subcarbonate 37,5 mg light kaolin 1,25 g pectin 56 mg

European Union - English - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contraindication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

European Union - English - EMA (European Medicines Agency)

"anpharm" przedsiębiorstwo farmaceutyczne s.a. - ivabradine - angina pectoris; heart failure - other cardiac preparations - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersor in combination with beta-blockers in patients inadequately controlled with an optimal betablocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectorisivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm.ivabradine is indicated :- in adults unable to tolerate or with a contra-indication to the use of beta-blockers- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.treatment of chronic heart failureivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. (see section 5.1)